MAPT and Alzheimer disease: Using thecalibrator samples to calculate the aggregate concentration, all sampleswere above zero, showing the detection of aggregates in these samples.Notably, we saw a significant increase in tau and p-tau aggregateswith AD (Figure 3B–G).The mean concentration of α-syn aggregates detected by SC211was 109 and 248 pM (SC211 assay, Welch’s t-test, p = 0.42) and 107 and 88 pM for aggregatesdetected by 4B12 (Welch’s t-test, p = 0.69), respectively in control and AD brains (Figure 3B,C), with no significantdifferences between control and disease.